Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.35
(
-1.03%
)
Bitcoin
70,180.29
(
0.40%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gofishmarko post# 31944

Thursday, 07/27/2006 4:18:46 PM

Thursday, July 27, 2006 4:18:46 PM

Post# of 257262
>This delay by VRTX may be why IDIX has made the coinfected cohort a priority for NM283. A good move, IMO, since coinfected patients are such a large chunk of the market.<

That’s part of the reason, IMO; another part of the reason is that IDIX is hedging in case the treatment-refractory setting does not pan out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now